Status:
COMPLETED
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Medarex
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this clinical research study is to evaluate the Best Overall Response Rate (BORR), (as per modified WHO criteria) in patients with previously treated melanoma-Stage III (unresectable) o...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with previously treated Stage III (unresectable)or Stage IV melanoma
Exclusion
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
155 Patients enrolled
Trial Details
Trial ID
NCT00289627
Start Date
April 1 2006
End Date
July 1 2007
Last Update
September 28 2016
Active Locations (53)
Enter a location and click search to find clinical trials sorted by distance.
1
Little Rock, Arkansas, United States
2
San Francisco, California, United States
3
Santa Monica, California, United States
4
Chicago, Illinois, United States